Étiquette : ratio CBD-THC

Chemical and Morphological Phenotypes in Breeding of Cannabis sativa L., Gianpaolo Grassi and John M. McPartland, 2017

Chemical and Morphological Phenotypes in Breeding of Cannabis sativa L. Gianpaolo Grassi and John M. McPartland in S. Chandra et al. (eds.), Cannabis sativa L. - Botany and Biotechnology, Chapter 6, 2017, 137-160. Doi : 10.1007/978-3-319-54564-6_6   Abstract This chapter has two parts. The first part details five characters that contribute to phenotypic diversity in Cannabis. Cannabinoids can be assayed by quantity (dry weight percentage of cannabinoids in harvested material) or by quality (the THC/CBD ratio, or chemotype). Cannabinoid quality is largely genetic, possibly monogenic. We dissect the monogenic inheritance model (two alleles at a single gene locus). Essential oil is composed of volatile, aromatic terpenoids. [...]

Lire la suite

Medical cannabis for severe treatment resistant epilepsy in children : a case-series of 10 patients, Rayyan Zafar, David Nutt et al., 2021

Medical cannabis for severe treatment resistant epilepsy in children : a case-series of 10 patients Rayyan Zafar, Anne Schlag, Lawrence Phillips, David J Nutt BMJ Paediatrics Open, 2021, 5, e001234. doi : 10.1136/bmjpo-2021-001234 ABSTRACT Objectives : To report the findings of a case-series of 10 children suffering with intractable epilepsies in the UK to determine the feasibility for using whole-plant cannabis medicines to treat seizures in children. Setting : This study was conducted retrospectively through collecting clinical data from caretakers and clinicians on study outcome variables. Participants were recruited through the MedCann Support and End our Pain charity groups which are patient representative groups that support children [...]

Lire la suite

Epidiolex Plus THC May Lower Seizures in Pediatric Epilepsy Randy Dotinga, Medscape.com, 2021.

Epidiolex Plus THC May Lower Seizures in Pediatric Epilepsy Randy Dotinga  Medscape.com - Oct 14, 2021. https://www.medscape.com/viewarticle/960842   Children and young adults with epilepsy had fewer seizures after combination treatment with the drug Epidiolex, which contains the cannabidiol (CBD), and various doses of tetrahydrocannabinol (THC), the component of cannabis that makes people high in larger quantities, researchers reported. "THC can contribute to seizure control and mitigation some of the side effects of CBD," said study coauthor and Austin, Tex., child neurologist Karen Keough, MD, in an interview. Keough and colleagues presented their findings at the 50th annual meeting of the Child Neurology Society. In a landmark move, the Food and [...]

Lire la suite

Medicinal use of cannabis based products and cannabinoids, Tom P Freeman et al., 2019

Medicinal use of cannabis based products and cannabinoids Tom P. Freeman, Chandni Hindocha, Sebastian F. Green, Michael A. P. Bloomfield British Medical Journal, 2019, 365, l1141 doi : 10.1136/bmj.l1141   What you need to know • Cannabis based products for medicinal use contain cannabinoids derived from the cannabis plant, including Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of THC and CBD. Synthetic cannabinoids for medicinal use typically mimic the effects of specific cannabinoids such as THC • THC is the constituent of cannabis that causes the “high,” whereas CBD is not intoxicating at typical doses. THC and CBD have contrasting mechanisms of action and therapeutic indications; THC [...]

Lire la suite

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial, Daryl Efron et al.,

Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial Daryl Efron, Kaitlyn Taylor, Jonathan M Payne, Jeremy L Freeman, Noel Cranswick, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Katrina Williams BMJ Open, 2020, 10, e034362. doi : 10.1136/bmjopen-2019-034362   Abstract Introduction : Severe behavioural problems (SBPs) are a common contributor to morbidity and reduced quality of life in children with intellectual disability (ID). Current medication treatment for SBP is associated with a high risk of side effects. Innovative and safe interventions are urgently needed. Anecdotal reports and preliminary research suggest that medicinal [...]

Lire la suite

Do medical cannabis growers attempt to produce cannabis with different cannabinoid concentrations than recreational growers?, Sharon R. Sznitman et al., 2019,

Do medical cannabis growers attempt to produce cannabis with different cannabinoid concentrations than recreational growers? Sharon R. Sznitman, Monica J. Barratt, Tom Decorte, Pekka Hakkarainen, Simon Lenton, Gary Potter, Bernd Werse and Chris Wilkins Drugs and Alcohol Today, 2019, 19, (4), 251-256, Doi : 10.1108/DAT-06-2019-0021   Abstract Purpose – It is conceivable that cannabis cultivators who grow for medical purposes aim to improve the therapeutic index of their cannabis by attempting to produce particular concentrations of CBD and/or THC. The purpose of this paper is to examine whether small-scalemedical cannabis growers differ fromthose growing for recreational reasons in terms of self-assessed concentrations of THC and CBD [...]

Lire la suite

Prescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva, Barbara Broers et al., 2019

Prescription of a THC/CBD-Based Medication to Patients with Dementia : A Pilot Study in Geneva Barbara Broers, Zacharie Patà, Aline Mina, James Wampfler, Christian de Saussure, Sophie Pautex Medical Cannabis & Cannabinoids, 2019, 2, 56–59 Doi : 10.1159/000498924 Abstract Background : Dementia is increasing worldwide. No effective medication is currently available for the treatment of the underlying disease and accompanying behavioral symptoms. Cannabinoids might have a beneficial effect, but clinical studies with (low-dose) synthetic THC have not been conclusive. Objective : To test the acceptability, practical aspects, and clinical outcomes of the introduction of a THC/ CBD-based oral medication in severely demented patients in a specialized [...]

Lire la suite

Medical cannibus as an alternative for opioids for chronic pain : A case report, Franklin E. Caldera, 2020

Medical cannibus as an alternative for opioids for chronic pain : A case report Franklin E. Caldera SAGE Open Medical Case Reports, 2020, Volume 8, 1–3 DOI : 10.1177/2050313X20907015   Abstract Opioid medication–related deaths have increased to epidemic proportions in the last decade. This report describes a case of 43-year-old female with a traumatic brain injury who developed chronic pain and opioid dependence. The patient expressed concerns and wanted weaning off opioids. Recent legalization of medical marijuana in Pennsylvania allows us to try it as an alternative to opioids for chronic pain. Medical cannibus has risks associated with administration but is safer than opioids. Our patient [...]

Lire la suite

Mapping cannabis potency in medical and recreational programs in the United States, Mary Catherine Cash et al., 2020

Mapping cannabis potency in medical and recreational programs in the United States Mary Catherine Cash, Katharine Cunnane, Chuyin Fan, E. Alfonso Romero-Sandoval PLoS ONE, 2020, 15, (3), e0230167. Doi : 10.1371/journal.pone.0230167     Opinion d'expert: Les allégations sur l'infaisabilité du cannabis avec des concentrations élevées de THC à des fins médicales ne sont pas étayées par la science En mars 2020, le conseil d'administration de l'IACM a décidé d'installer une nouvelle catégorie dans le Bulletin de l’IACM, qui encourage à rédiger des opinions et des déclarations de chercheurs sur les rapports scientifiques actuels et des déclarations de collègues. Ces avis visent à stimuler la discussion sur [...]

Lire la suite

Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches, Marcel O. Bonn-Miller et al., 2018

Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches Marcel O. Bonn-Miller, Mahmoud A. ElSohly, Mallory J. E. Loflin, Suman Chandra and Ryan Vandrey International Review of Psychiatry, 2018, VOL. 30, NO. 3, 277–284 Doi : 10.1080/09540261.2018.1474730   ABSTRACT Accumulating evidence suggests that the endocannabinoid system is a promising target for the treatment of a variety of health conditions. Two paths of cannabinoid drug development have emerged. One approach is focused on developing medications that are directly derived from the cannabis plant. The other utilizes a single molecule approach whereby individual phytocannabinoids or novel cannabinoids with therapeutic potential are identified and synthesized for pharmaceutical [...]

Lire la suite